Assertive Community Treatment for Patients Suffering From Substance Use Disorders
Assertive Community Treatment for Patients Suffering From Substance Use
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Geneva, Switzerland, 1202
- Service d'addictologie, HUG
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Substance use disorder
- Competent subjects, able to give informed consent
- French speaking
Exclusion Criteria:
- Evidence of organic brain disease or learning disability based on the chart review.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Assertive Community Treatment
patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years. or (2) difficulties to attend their health care appointments, during the last 3 months. |
The intervention program is a type of very flexible community treatment.
This is facilitated by a small case load ratio per health care professional (1:10).
The healthcare workers are specialized in SUD treatment.
The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient.
The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient.
The intervention aims to prevent service disengagement.
The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment adherence
Time Frame: at 12 months
|
Number of days until service disengagement
|
at 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient network
Time Frame: 0, 3, 6, 12 months
|
Number of persons in network
|
0, 3, 6, 12 months
|
|
Service use
Time Frame: at 12 months
|
Number of hospital admissions and number of days in hospital
|
at 12 months
|
|
Number of ER visits
Time Frame: 0, 3, 6, 12 months
|
Number of ER visits reviewed on patient file
|
0, 3, 6, 12 months
|
|
Addictive behaviour
Time Frame: 0, 3, 6, 12 months
|
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST.
V.3 French)
|
0, 3, 6, 12 months
|
|
General psychiatric symptoms
Time Frame: 0, 3, 6, 12 months
|
Health of Nation Outcome Scale - French version (HoNOS-F): scores 0 - 52 (higher score = more psychiatric symptoms)
|
0, 3, 6, 12 months
|
|
Global Functioning
Time Frame: 0, 3, 6, 12 months
|
World Health Organization Disability Assessment Schedule (WHODAS)
|
0, 3, 6, 12 months
|
|
General life satisfaction: Satisfaction With Life Scale
Time Frame: 0, 3, 6, 12 months
|
Satisfaction With Life Scale: scores 5 - 35 (higher score = higher life satisfaction)
|
0, 3, 6, 12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient satisfaction with Assertive Community Treatment
Time Frame: at 3, 6, 12 months
|
Patient satisfaction with Assertive Community Treatment (very satisfied, satisfied, more or less satisfied, not satisfied
|
at 3, 6, 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Louise Penzenstadler, MD, University Hospital, Geneva
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ID 2017-01087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.